Vimgreen Pharmaceuticals Gains IND Approval for Groundbreaking NASH Therapy with VG081821 Vimgreen Pharmaceuticals has received IND approval for VG081821, an innovative therapy targeting NASH/MASH, marking a significant advance in liver disease treatment.

Vimgreen Pharmaceuticals Gains IND Approval for Groundbreaking NASH Therapy with VG081821 #China #Hangzhou #NASH #Vimgreen #VG081821